Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 9/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888436 | 0.92 | FAAH (0.45) | GRIN1GRIN2BGRM2FAAHNAAA | |
| SCHEMBL1644490 | 0.81 | FFAR1 (0.45) | GRM2 | |
| SCHEMBL31068302 | 0.80 | GRIN1 (0.43) | GRIN1GRIN2BGRM2PIK3CD | |
| SCHEMBL29348962 | 0.80 | GRIN1 (0.43) | GRIN1GRIN2BGRM2PIK3CD | |
| SCHEMBL6886663 | 0.79 | L3MBTL1 (0.55) | ENPP2ACHEPORCN | |
| SCHEMBL6885909 | 0.77 | ENPP2 (0.43) | GRIN1GRIN2BGRM2ENPP2ACHE | |
| SCHEMBL6886132 | 0.77 | ENPP2 (0.41) | GRM2ENPP2CHRM5SRC | |
| SCHEMBL6885194 | 0.76 | IL4I1 (0.53) | GRIN1GRIN2BGRM2FAAHNAAA | |
| SCHEMBL9016265 | 0.74 | GRM2 (0.56) | GRM2FAAHNAAAPIK3CD | |
| SCHEMBL6885814 | 0.74 | PRMT5 (0.46) | GRM2ENPP2CHRM5PORCN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2011051201-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | GRIN1 8/4885GRIN2B 21/4885GRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.